<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">6. Angiogenesis in Glioblastomas</segment>
<segment id="2" parent="1003" relname="span">Features of glioblastomas are a high propensity</segment>
<segment id="3" parent="2" relname="purpose">to invade the surrounding tissues and extensive angiogenesis .</segment>
<segment id="4" parent="1004" relname="span">They are characterized by a pathological vascular system with a dense network of winding vessels of different diameters , increased permeability , and with abnormally thickened basement membranes .</segment>
<segment id="5" parent="1005" relname="span">These properties are often the cause of relapses and therapy failures</segment>
<segment id="6" parent="5" relname="cause">because they hinder tumor access to cytotoxic chemotherapy .</segment>
<segment id="7" parent="1008" relname="span">Angiogenesis</segment>
<segment id="8" parent="7" relname="elaboration">caused by the presence of a tumor</segment>
<segment id="9" parent="1009" relname="span">is defined as the formation of new blood vessels</segment>
<segment id="10" parent="1010" relname="span">based on existing ones ,</segment>
<segment id="11" parent="10" relname="elaboration">which can be visualized using ultra-high-field magnetic resonance angiography .</segment>
<segment id="12" parent="1013" relname="span">The mechanism of this process is very complex .</segment>
<segment id="13" parent="12" relname="elaboration">In GBM , the development of pathological vasculature is based on changes in adhesion molecules on the endothelial surface , the presence of an erratic basement membrane , a decrease in pericyte coverage , and a weaker binding of astrocytes to blood vessels .</segment>
<segment id="14" parent="1015" relname="span">A common element for the large invasiveness and angiogenesis of glioblastomas is the loss of tumor cell boundaries with the surrounding microenvironment</segment>
<segment id="15" parent="14" relname="elaboration">consisting of brain tissue , subarachnoid space , and blood vessels .</segment>
<segment id="16" parent="1017" relname="span">Angiogenesis occurs under the influence of various mechanisms ,</segment>
<segment id="17" parent="16" relname="elaboration">which we divide into hypoxia-dependent and hypoxia-independent .</segment>
<segment id="18" parent="1018" relname="joint">Hypoxia has been proven to inactivate prolyl hydroxylases .</segment>
<segment id="19" parent="1020" relname="span">This increases the level of hypoxia-inducible factor-1α</segment>
<segment id="20" parent="19" relname="elaboration">( HIF-1α ) ,</segment>
<segment id="21" parent="1022" relname="span">causing the release of vascular endothelial growth factor</segment>
<segment id="22" parent="21" relname="restatement">( VEGF )</segment>
<segment id="23" parent="1023" relname="span">by glioma cells</segment>
<segment id="24" parent="23" relname="elaboration">affected by hypoxia .</segment>
<segment id="25" parent="1025" relname="span">The task of VEGF is to counteract oxygen deficiency</segment>
<segment id="26" parent="25" relname="means">by inducing vascular network growth .</segment>
<segment id="27" parent="1027" relname="joint">In spite of this ,</segment>
<segment id="28" parent="1027" relname="joint">hypoxia may not be the only trigger factor for angiogenesis .</segment>
<segment id="29" parent="1029" relname="span">This applies particularly to the initial stages of carcinogenesis ,</segment>
<segment id="30" parent="29" relname="circumstance">when cell hypoxia is not yet severe .</segment>
<segment id="31" parent="1031" relname="span">Regulation of VEGF secretion also takes place by a mechanism independent of hypoxia ,</segment>
<segment id="32" parent="31" relname="elaboration">involving dysregulated activation of mitogenic and survival pathways .</segment>
<segment id="33" parent="1032" relname="joint">This applies to phosphatidylinositol 3-kinase and Ras/mitogen-activated protein kinase .</segment>
<segment id="34" parent="1034" relname="span">The PD-L1/PD-1 axis may also have roles</segment>
<segment id="35" parent="1035" relname="span">in regulating the level of VEGF</segment>
<segment id="36" parent="35" relname="elaboration">mediating angiogenesis .</segment>
<segment id="37" parent="1037" relname="span">In studies</segment>
<segment id="38" parent="37" relname="elaboration">conducted by Shin et al. , a positive correlation between PDL1 levels and VEGF expression was shown in 197 patients with renal cell carcinoma .</segment>
<segment id="39" parent="1039" relname="joint">Similar observations were noted by Song et al. The study was conducted in 64 patients with primary glioma .</segment>
<segment id="40" parent="41" relname="attribution">Also , they showed</segment>
<segment id="41" parent="1041" relname="span">that PD-L1 expression levels correlated well with VEGF levels .</segment>
<segment id="42" parent="1042" relname="span">However , not all studies agreed on this point .</segment>
<segment id="43" parent="1043" relname="span">Research by Joseph et al. indicates the existence of a negative relationship between VEGF-related genes and the activity of the PD-L1/PD1 axis .</segment>
<segment id="44" parent="1044" relname="span">A thorough understanding of the nature of this relationship requires further work .</segment>
<segment id="45" parent="1045" relname="joint">EGF is another molecule with similar effects .</segment>
<segment id="46" parent="1047" relname="span">It promotes tumor angiogenesis as well as an increase in cell motility and invasiveness .</segment>
<segment id="47" parent="1048" relname="span">This is done</segment>
<segment id="48" parent="1049" relname="joint">by phosphorylating the EGFR receptor</segment>
<segment id="49" parent="1049" relname="joint">and activating further signaling pathways .</segment>
<segment id="50" parent="51" relname="attribution">It has been shown</segment>
<segment id="51" parent="1051" relname="span">that both EGFR and its mutated form of EGFRvIII promote GBM angiogenesis .</segment>
<segment id="52" parent="53" relname="condition">To allow vasculature growth and tumor invasion ,</segment>
<segment id="53" parent="1053" relname="span">it is necessary to reduce the integrity of the tumor microenvironment .</segment>
<segment id="54" parent="1054" relname="span">The pathophysiology of this process is based on EGFR inducing an increase in the activity of some proteases ,</segment>
<segment id="55" parent="54" relname="elaboration">thereby causing the breakdown of collagen , fibronectin , and other basement membrane structures .</segment>
<segment id="56" parent="1055" relname="span">The result is a loss of microenvironment integrity , an increase in tumor cell invasion into surrounding tissues and vessels , and an increase in angiogenesis .</segment>
<segment id="57" parent="1057" relname="span">The proteases</segment>
<segment id="58" parent="57" relname="elaboration">whose activity is influenced by EGFR include , among others :</segment>
<segment id="59" parent="1058" relname="joint">Serine Proteases</segment>
<segment id="60" parent="1060" relname="span">Matrix Metalloproteases</segment>
<segment id="61" parent="60" relname="restatement">( MMPs )</segment>
<segment id="62" parent="1061" relname="joint">Cysteine Proteases .</segment>
<segment id="63" parent="1064" relname="span">Serine proteases are a large group of proteases</segment>
<segment id="64" parent="1065" relname="span">which include tissue plasminogen activator</segment>
<segment id="65" parent="64" relname="restatement">( tPA )</segment>
<segment id="66" parent="1067" relname="span">and urokinase plasminogen activator</segment>
<segment id="67" parent="66" relname="restatement">( uPA )</segment>
<segment id="68" parent="1068" relname="span">with its receptor</segment>
<segment id="69" parent="68" relname="elaboration">( uPAR ) .</segment>
<segment id="70" parent="1070" relname="span">Their activation affects the degradation of the extracellular space by tumors ,</segment>
<segment id="71" parent="70" relname="elaboration">promoting their invasiveness .</segment>
<segment id="72" parent="73" relname="attribution">It has been shown</segment>
<segment id="73" parent="1072" relname="span">that , the PAI-1 molecule mediates the regulation of the uPA/uPAR pathway in astrocytoma cells .</segment>
<segment id="74" parent="1073" relname="span">Its expression is promoted by an increase in EGF and inflammatory cytokines .</segment>
<segment id="75" parent="1075" relname="span">This results in greater uPA/uPAR activity ,</segment>
<segment id="76" parent="75" relname="result">thus increasing tumor invasiveness .</segment>
<segment id="77" parent="1077" relname="span">Upregulation of uPA and uPAR is also achieved through the expression of the EGFR ligand transforming growth factor</segment>
<segment id="78" parent="77" relname="restatement">( TGFα ) .</segment>
<segment id="79" parent="80" relname="attribution">Studies confirmed</segment>
<segment id="80" parent="1079" relname="span">that in malignant gliomas , both PAI-1 and EGFR activity correlate with higher tumor malignancy and worse prognosis for patients .</segment>
<segment id="81" parent="1080" relname="joint">EGF also has a potential impact on another group of proteases , i.e. , MMPs .</segment>
<segment id="82" parent="1082" relname="span">They are a large group of enzymes</segment>
<segment id="83" parent="82" relname="elaboration">whose effect is based on the regulation of metabolism and cell morphogenesis .</segment>
<segment id="84" parent="1083" relname="joint">Disruption of their function also affects the loss of cell integrity .</segment>
<segment id="85" parent="1086" relname="attribution">It has been shown</segment>
<segment id="86" parent="1087" relname="span">that the activity of certain matrix metalloproteases , such as MMP-2</segment>
<segment id="87" parent="86" relname="elaboration">( gelatinase A ) ,</segment>
<segment id="88" parent="1089" relname="span">MMP-9</segment>
<segment id="89" parent="88" relname="elaboration">( gelatinase B ) ,</segment>
<segment id="90" parent="1091" relname="span">MMP-14</segment>
<segment id="91" parent="90" relname="restatement">( matrix metalloproteinase 14 )</segment>
<segment id="92" parent="1090" relname="same_unit">is related to the pathophysiology of high-grade gliomas .</segment>
<segment id="93" parent="1092" relname="joint">It correlates with the severity of tumor invasion and its degree of malignancy .</segment>
<segment id="94" parent="1094" relname="span">Another group of proteases are cysteine proteases ,</segment>
<segment id="95" parent="94" relname="elaboration">examples of which are cathepsins .</segment>
<segment id="96" parent="1096" relname="span">These include , among others , cathepsin B ,</segment>
<segment id="97" parent="96" relname="elaboration">involved in the degradation of the tumor microenvironment .</segment>
<segment id="98" parent="1099" relname="span">Its expression</segment>
<segment id="99" parent="98" relname="elaboration">( mRNA level )</segment>
<segment id="100" parent="1098" relname="same_unit">has been shown to correlate with EGFR expression level .</segment>
<segment id="101" parent="102" relname="attribution">It was also confirmed</segment>
<segment id="102" parent="1102" relname="span">that its presence is increased in gliomas .</segment>
<segment id="103" parent="1102" relname="elaboration">The action of cathepsin B may be bidirectional .</segment>
<segment id="104" parent="1101" relname="elaboration">It promotes the degradation of the integrity of the environment of the tumor directly or through intermediate mediators such as uPA , MMPs , or plasmin .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="elaboration"/>
<group id="1005" type="span" parent="4" relname="elaboration"/>
<group id="1006" type="multinuc" parent="1002" relname="elaboration"/>
<group id="1007" type="multinuc" parent="1006" relname="joint"/>
<group id="1008" type="span" parent="1007" relname="same_unit"/>
<group id="1009" type="span" parent="1007" relname="same_unit"/>
<group id="1010" type="span" parent="9" relname="elaboration"/>
<group id="1011" type="multinuc" parent="1006" relname="joint"/>
<group id="1012" type="span" parent="1011" relname="joint"/>
<group id="1013" type="span" parent="1014" relname="preparation"/>
<group id="1014" type="multinuc" parent="1012" relname="span"/>
<group id="1015" type="span" parent="1014" relname="joint"/>
<group id="1016" type="span" parent="1014" relname="joint"/>
<group id="1017" type="span" parent="1016" relname="span"/>
<group id="1018" type="multinuc" parent="1017" relname="elaboration"/>
<group id="1019" type="multinuc" parent="1018" relname="joint"/>
<group id="1020" type="span" parent="1019" relname="same_unit"/>
<group id="1021" type="multinuc" parent="1019" relname="same_unit"/>
<group id="1022" type="span" parent="1021" relname="same_unit"/>
<group id="1023" type="span" parent="1021" relname="same_unit"/>
<group id="1024" type="multinuc" parent="1011" relname="joint"/>
<group id="1025" type="span" parent="1024" relname="joint"/>
<group id="1026" type="multinuc" parent="1024" relname="joint"/>
<group id="1027" type="multinuc" parent="1026" relname="joint"/>
<group id="1028" type="multinuc" parent="1026" relname="joint"/>
<group id="1029" type="span" parent="1028" relname="joint"/>
<group id="1030" type="multinuc" parent="1028" relname="joint"/>
<group id="1031" type="span" parent="1030" relname="joint"/>
<group id="1032" type="multinuc" parent="1030" relname="joint"/>
<group id="1033" type="multinuc" parent="1032" relname="joint"/>
<group id="1034" type="span" parent="1033" relname="joint"/>
<group id="1035" type="span" parent="34" relname="elaboration"/>
<group id="1036" type="multinuc" parent="1033" relname="joint"/>
<group id="1037" type="span" parent="1036" relname="joint"/>
<group id="1038" type="multinuc" parent="1036" relname="joint"/>
<group id="1039" type="multinuc" parent="1038" relname="joint"/>
<group id="1040" type="multinuc" parent="1039" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="contrast"/>
<group id="1042" type="span" parent="1040" relname="contrast"/>
<group id="1043" type="span" parent="42" relname="elaboration"/>
<group id="1044" type="span" parent="43" relname="elaboration"/>
<group id="1045" type="multinuc" parent="44" relname="elaboration"/>
<group id="1046" type="span" parent="1045" relname="joint"/>
<group id="1047" type="span" parent="1046" relname="span"/>
<group id="1048" type="span" parent="46" relname="elaboration"/>
<group id="1049" type="multinuc" parent="47" relname="means"/>
<group id="1050" type="multinuc" parent="1047" relname="elaboration"/>
<group id="1051" type="span" parent="1050" relname="joint"/>
<group id="1052" type="multinuc" parent="1050" relname="joint"/>
<group id="1053" type="span" parent="1052" relname="joint"/>
<group id="1054" type="span" parent="1052" relname="joint"/>
<group id="1055" type="span" parent="1038" relname="joint"/>
<group id="1056" type="span" parent="56" relname="elaboration"/>
<group id="1057" type="span" parent="1058" relname="preparation"/>
<group id="1058" type="multinuc" parent="1056" relname="span"/>
<group id="1059" type="multinuc" parent="1058" relname="joint"/>
<group id="1060" type="span" parent="1059" relname="joint"/>
<group id="1061" type="multinuc" parent="1059" relname="joint"/>
<group id="1062" type="multinuc" parent="1061" relname="joint"/>
<group id="1063" type="multinuc" parent="1062" relname="joint"/>
<group id="1064" type="span" parent="1063" relname="same_unit"/>
<group id="1065" type="span" parent="63" relname="elaboration"/>
<group id="1066" type="multinuc" parent="1063" relname="same_unit"/>
<group id="1067" type="span" parent="1066" relname="same_unit"/>
<group id="1068" type="span" parent="1066" relname="same_unit"/>
<group id="1069" type="multinuc" parent="1062" relname="joint"/>
<group id="1070" type="span" parent="1069" relname="joint"/>
<group id="1071" type="multinuc" parent="1069" relname="joint"/>
<group id="1072" type="span" parent="1071" relname="joint"/>
<group id="1073" type="span" parent="1071" relname="joint"/>
<group id="1074" type="multinuc" parent="74" relname="elaboration"/>
<group id="1075" type="span" parent="1074" relname="joint"/>
<group id="1076" type="multinuc" parent="1074" relname="joint"/>
<group id="1077" type="span" parent="1076" relname="joint"/>
<group id="1078" type="multinuc" parent="1076" relname="joint"/>
<group id="1079" type="span" parent="1078" relname="joint"/>
<group id="1080" type="multinuc" parent="1078" relname="joint"/>
<group id="1081" type="multinuc" parent="1080" relname="joint"/>
<group id="1082" type="span" parent="1081" relname="joint"/>
<group id="1083" type="multinuc" parent="1081" relname="joint"/>
<group id="1084" type="multinuc" parent="1083" relname="joint"/>
<group id="1085" type="span" parent="1084" relname="joint"/>
<group id="1086" type="multinuc" parent="1085" relname="span"/>
<group id="1087" type="span" parent="1086" relname="same_unit"/>
<group id="1088" type="multinuc" parent="1086" relname="same_unit"/>
<group id="1089" type="span" parent="1088" relname="same_unit"/>
<group id="1090" type="multinuc" parent="1088" relname="same_unit"/>
<group id="1091" type="span" parent="1090" relname="same_unit"/>
<group id="1092" type="multinuc" parent="1084" relname="joint"/>
<group id="1093" type="multinuc" parent="1092" relname="joint"/>
<group id="1094" type="span" parent="1093" relname="joint"/>
<group id="1095" type="multinuc" parent="1093" relname="joint"/>
<group id="1096" type="span" parent="1095" relname="joint"/>
<group id="1097" type="multinuc" parent="1095" relname="joint"/>
<group id="1098" type="multinuc" parent="1097" relname="joint"/>
<group id="1099" type="span" parent="1098" relname="same_unit"/>
<group id="1100" type="span" parent="1097" relname="joint"/>
<group id="1101" type="span" parent="1100" relname="span"/>
<group id="1102" type="span" parent="1101" relname="span"/>
	</body>
</rst>
